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Abstract
Cervical cancer is a public health burden to Low and Middle Income countries. Whereas 
strides are being made in the management of malignancies worldwide, resources limited 
settings are confronted with the paucity of basic awareness, health professionals, diag-
nosis and management modalities, all contributing to cervical cancer disease late pre-
sentation. Among available treatment modalities, the mainstay of treatment for locally 
advanced cervical cancer remains radiation therapy combined with chemotherapy. 
Radiation is delivered through external radiation and brachytherapy. The evidence lead-
ing to the decision making, the modern management modalities and the general side 
effects, will be reviewed here.
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1. Introduction
Cervical cancer represents the second most common malignancy and the third overall cause 
of cancer mortality in Low and Middle Income Countries (LMICs) [1]. Such countries contrib-
ute the majority of the cervical cancer burden worldwide.
The FIGO classification system, endorsed by the American Joint Commission on Cancer 
2017, defines locally advanced cervical cancer, as a disease found between stages IB2 to IVA 
[2]. This subset of diseases is visible on clinical examination and usually predict worse out-
come in terms of recurrence and survival rates when compared to early stage disease.
Several studies focusing on the different stages at initial presentation have shown consistently 
high rates of advanced disease in LMICs (Table 1).
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Advanced stages present a considerable challenge to achieving adequate treatment. This is 
compounded by the absence of modern treatment modalities and technologies that are avail-
able in high-income countries (HIC).
LMICs face a double burden where patients for different reasons including health system fac-
tors presents at hospital with advanced diseases and at the same time there is a pronounced 
lack of infrastructure to take care of these patients. This leads to an overall poor survival rates.
2. Disease evaluation
Staging with full nodal evaluation remains a crucial aspect of the management of locally 
advanced cervical carcinoma.
Studies Type Country Patients (N) Stage (rate percentage) at presentation
Chirenje et al. [5] CS2 Zimbabwe 196 Stages IIB - IVA: (80.3%)




















IVA (8.7%); IVB (1.9%)
1R = retrospective review.
2CS = cross-sectional study.
Table 1. Summary of rates of cervical carcinoma disease stage at presentation in LMICs.
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The pattern of spread of cervical cancer follows principles seen in numerous other solid 
malignancies namely, local extension, lymphatic spread and distant metastasis.
The disease usually spreads directly distally to the vagina, with extension along the parame-
tria, the uterine ligaments (commonly utero-sacral) and the peri-rectal area.
Lymphatic spread occurs by echelon from the pelvic nodes, usually proximally toward the 
para-aortic nodes, and could substantially lead to left supraclavicular lymph node involve-
ment in rare cases.
There is a high correlation between nodal status and disease outcomes. Contemporary studies 
have estimated close to 40% of survival at 5-years follow-up if evidence of para-aortic node 
involvement is established. Risk of nodal metastasis increases approximately by 15% for each 
stage, from FIGO stage I to III.
A Computed-Tomography (CT) guided biopsy is needed for nodal disease confirmation. For 
expert centers, an F-18 fluorodeoxyglucose-based positron emission tomography (PET) scan 
is necessary to establish nodal disease.
The patient needs also to be screened for competing risk factors. Importantly, patients should 
be evaluated for present or acquired (by local extension, Stage IIIB) kidney disease as the 
management of locally advanced cervical carcinoma incorporates the use of platinum-based 
chemotherapy as a radio-sensitizer. Corrections to the management protocols related to the 
renal disease stage have been suggested and carry promising grounds for further prospective 
studies.
Disease staging provides ground for prognosis, local control and survival prediction in the 
presence of adequate management modalities. Survival rates vary across studies and are 
inversely related to stage, with disease control and 5-year overall survival both ranging from 
90% for stage IB to only close to 30% for stage IVA, in recent studies.
For aggregate analyses of locally advanced cervical carcinoma management outcome-based 
studies, newer treatment techniques are providing encouraging survival data.
3. Locally advanced cervical carcinoma management
The standard of care for advanced cervical carcinoma is Radiation Therapy alone (in case of 
palliation), or in combination with cisplatin-based chemotherapy.
Overall survival is usually a function of disease-free interval rates, highlighting the scarcity of 
salvage therapy options in case of recurrence.
With limited options for salvage in cases of recurrences, disease-free interval rates directly 
correlate to Overall Survival and comorbidities of the patients.
Generally, management of cervical carcinoma includes definitive surgery for selected cases, 
upfront radiation therapy and chemo-radiation. Surgery and radiation therapy amount to the 
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same effect yet with drastic differences in terms of debilitating toxicities, hence surgery alone 
is the treatment of choice for initial smaller lesions (<4 cm) with other treatment modalities 
offered as a salvage in case of recurrence.
4. Primary chemoradiation vs. surgery
As cited above, the widely used treatment scheme for locally advanced cervical carcinoma 
consists of upfront radiotherapy concurrently with a platinum-based chemotherapy.
Surgery has been proven to not be superior to chemo-radiation, but carries twice a risk of 
increased toxicity rates.
Adverse features arising post-surgery could be similar to other advanced diseases, including 
high grade disease, lympho-vascular space invasion (LVSI), positive lymph nodes, prompting 
the use of multiple modalities of treatment with subsequent considerable toxicities.
The largest comparison study to date by Landoni, compared 343 patients with early disease, 
contemporarily included in the locally advanced stage (IB - IIA) disease, to undergo an exten-
sive surgery with pelvic lymph node dissection, with a possibility of Radiation Therapy boost 
in the presence residual disease. This arm was compared with upfront Radiation Therapy. 
The comparison yielded no differences in survival, but showed considerable difference in 
toxicity rates [7].
Chemo-radiation has been proven to offer a high survival benefit which is greatly influenced 
by disease stage. Additionally, concurrent chemo-radiation decreases the recurrence risk.
Radiation consists of external beam radiotherapy session and a stage-variable boosting dose 
achieved by brachytherapy. Details on patient simulation, field size and dose specification 
are found below.
5. Combined radiation and chemotherapy regimen
5.1. Chemotherapy regimens
Concurrent radiation with chemotherapy has come to age relatively recently, with cisplatin-
based chemotherapy rising at the dawn of the twenty-first century.
Before this era, numerous institutional trials had been published with various chemotherapy 
regimens selections.
Among previously suggested regimens, hydroxyurea was used in the 1960s, perceived as 
being a radiosensitizer. Hydroxyurea induces a block on the G1-S phase of the cell cycle, 
hence enhancing cell kill by radiation; prevention of sub-lethal damage repair has also been 
proven.
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A Gynecological Oncology Group (GOG 56) study confirmed the benefit of added hydroxyurea 
to radiation therapy, with a higher Progression Free interval, though no significant survival 
benefit was found [8]. This study was controversial in its setting and the recommendations 
were not applied widely. Hydroxyurea involves a high risk of myelosuppression, and pros-
pects of considering it as a viable combination therapy to radiation were abandoned overtime.
5-Fluorouracil has also been considered as an alternative chemotherapy regimen for combi-
nation therapy. However, the few published studies failed to prove local disease control and 
survival benefit with an added 5-Fluorouracil regimen [9].
Based on a five-study analysis, cisplatin added to radiation therapy was confirmed to have a 
superior survival when compared to radiation alone.
A large systematic review of 18 trials combining radiation and chemotherapy for locally advanced 
cervical carcinoma proved the survival benefit of adding chemotherapy. Platinum based che-
motherapy was not seen to be significantly different from non-platinum based chemotherapy 
(HR: 0.84 vs. 0.76, p = 0.48). Platinum-based regimens were also found to have a non-significant 
increased toxicity trend. However, single agent platinum offered an important alternative with 
regards to local disease control, adherence to treatment and ease of administration.
Historically, the GOG 120 compared different chemo-radiation regimens, combined with a 
brachytherapy boost. The arms had a cisplatin alone, a hydroxyurea alone and a cisplatin/5-
Fluorouracil/Hydroxyurea components. The arms containing cisplatin had improved survival 
and disease down-staging was achieved. Subsequent studies removed hydroxyurea and com-
pared upfront radiation therapy with concurrent cisplatin (with or without 5-Fluorouracil) 
with radiation therapy, which established the standard of care of adding chemotherapy to 
radiation therapy, as it was shown to increase survival and decrease recurrence risks.
The rationale behind adding cisplatin to radiation is that it acts as a radiosensitizer, by pre-
venting the Non-Homologous End Joining pathway, which is paramount in the Double Strand 
Breaks repair. Double Strand Breaks in DNA are induced by high energy radiation therapy.
Cisplatin is given on a weekly basis, a few hours before radiation therapy, and care needs to 
be taken for its administration. As a nephrotoxic agent, adequate hydration is to be ensured, 
before and after cisplatin infusion. Together with knowing prior the renal status of the patient, 
dosing can be altered to prevent toxicity. Carboplatin has been shown to provide a suitable 
alternative to cisplatin for patients who are not candidates to cisplatin infusion (Table 2).
Gemcitabine could also be a choice when cisplatin is contraindicated. However, in the absence 
of level I evidence, and with the increased toxicity risk associated with Gemcitabine, carbo-
platin remains the preferred choice in case of intolerance to cisplatin, and deranged renal 
function tests.
5.2. Radiation therapy
Radiation Therapy is provided by both External Beam Radiation (EBRT) and brachytherapy 
(BT) to increase local control.
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Total doses above 45 Gy are preferred as they are proven to offer a survival advantage.
Radiation therapy is offered to post-operative patients confirmed to have adverse features 
(mainly Lympho-Vascular Space Invasion, positive pelvic nodes, involved parametria and 
positive surgical margins), with stages IA2, IB. It is also the definitive treatment, with concur-
rent chemotherapy for stage IIB- IVA.
The typical dose given by EBRT varies between 45 and 50 Gy depending on the stage and 
prior treatment. For patients treated with a prior hysterectomy, lower doses (typically below 
45 Gy) are preferred to avoid radiation induced bowel toxicity; higher doses are safe to be 
delivered on an intact uterus and cervix.
Current RTOG and GOG protocols suggest total doses for cervical carcinoma treated with 
definitive radiation therapy to be around 80–90 Gy to a point defined within the paracervical 
triangle, namely the point A.
The point A has been varied over the years, and is defined as being at 2 cm above the external 
cervical os and 2 cm lateral to uterus midline. This corresponds to the paracervical triangle, 
where the uterine vessels cross the ureter, medial to the broad ligament.
Given the proximity of the cervix to the major pelvic organs and the femoral heads, the 
external beam radiation doses are limited to an overall dose of 50 Gy. Institutional practices 
vary, some preferring doses below 45 Gy before proceeding to brachytherapy, with options 
of lowering the field size to boost to gross residual and nodal disease to doses up to 50 Gy.
Addition of brachytherapy has shown high rates of cancer-specific and overall survival bene-
fits when compared to external beam radiation therapy alone. The objective of brachytherapy 
addition is to reach the desired total dose of 80–90 Gy to the disease site while minimizing 
toxicity to organs at risk.
5.3. External beam radiation techniques
The distal most part of the disease needs to be marked with radiopaque gold seeds for disease 
localization prior to treatment imaging. In the absence of gold seeds, radiopaque materials 
Cisplatin - dosage and premedications Details
Prior to Treatment Work-up Complete Blood Count - with a low Absolute Neutrophil Count, consider 
adding Filgrastim (if available) prior to chemotherapy infusion
Renal Function Tests - use the Glomerular Filtration Rate to determine 
fitness of the patient to receive cisplatin
Serum Electrolytes (K+, Na+)
Dosage 40 mg/m2 IV weekly
Pre-medications Hydration – 2 l Normal Saline (0.9%) over 2 hours prior and after a cisplatin 
infusion
Ondansetron 16 mg IV and Dexamethasone 16 mg IV, both mixed with 
100 ml of Normal Saline (0.9%)
Table 2. Summary—cisplatin treatment planning and dosage.
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such as lead or steel-made wires can be used for disease localization. The same needs to be 
applied to the vagina and anus areas.
For a 4-field (antero-posterior, postero-anterior and lateral fields) treatment, the simulation is 
done in the supine position and CT or Fluoroscopic images taken. Patients are positioned with 
arms on the chest, knees and lower legs immobilized. Anterior and lateral tattoos are marked 
and aligned with lasers for lateral rotation prevention. Obese patients may benefit from prone 
belly boards, to avoid small bowel inclusion in the radiation volume.
Intra-venous contrast CT scans are taken to help highlight the pelvic vessels used as reference 
to delineate the pelvic nodes.
For centers using two-dimensional planning and fluoroscopic imaging, the same marking has 
to be done, with fluorescent markers, and tattoos where applicable.
The borders are:
• Superior: Lumbar spine level 4/5
• Lateral: 1.5–2 cm away from the pelvic brim
• Anterior: 1 cm anterior to pubic symphysis
• Posterior: Entire Sacrum to be included
• Inferior: Below the ischial tuberosity or the inferior obturator foramen if bony landmarks 
are used
For advanced disease involving the lower vagina (stage IIIA), include at least a margin of 3 cm 
away from the distal most part of the disease.
Extensive Radiation Therapy has been suggested in the presence of para-aortic lymph nodes, 
with the superior-most border being T12/L1, with kidney blocks [10].
Stage IIIA is associated with inguinal nodes, and the field needs to include the vaginal introi-
tus as the inferior border; with a common iliac nodes disease presence, the superior border is 
to be raised up to L3/4.
Dosing should be up to 50 Gy delivered in 25 equal fractions, daily. This is usually given 
within 5 days a week for 5 weeks, allowing a 2-day rest between weeks of treatment.
Dose limiting organs are mainly the bladder, rectum, femoral heads, and with a lower instance, 
the small bowel and ovaries.
5.4. Brachytherapy
As per the American Brachytherapy Society guidelines, brachytherapy for cervical cancer 
needs to be applied for a disease not exceeding a size of 5 cm.
The preferred brachytherapy technique is the High Dose Rate Brachytherapy, delivering above 
12 Gy/hour.
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The point of interest for brachytherapy delivery is defined in the contemporary method as 
per the Manchester point A - 2 cm superior to the external cervical os and 2 cm lateral to the 
central uterine canal. The objective is to deliver a cumulative dose of 80–90 Gy.
Due to nodal disease associated with locally advanced cervical cancer, a Manchester point B 
is defined at 3 cm lateral to point A. With this system, bladder, vaginal and rectal points are 
also defined. Care needs to be taken to minimize the radiation dose to the bladder and rec-
tum by anteriorly and posteriorly packing through the vagina and around the brachytherapy 
applicators.
Brachytherapy delivery is provided once weekly over a time interval of 3–6 weeks. Total radio-
therapy treatment (EBRT and BT) should be completed within a time period of 7–8 weeks.
6. Complications
Acute complications commonly include local features, consisting with dry and moist skin 
desquamation, vaginitis, cystitis, and proctitis. Management of these complications varies 
between anti-inflammatory medications and anti-microbial drugs given for prophylaxis.
Brachytherapy side effects are mainly due to neighboring organ toxicity and include vaginitis, 
cystitis and uterine perforation.
Late complications include vaginal stenosis, recto-vaginal and vesico-vaginal fistula and intes-
tinal perforation.
7. Conclusions
With increasing rates of advanced cervical cancer disease in Low and Middle Income coun-
tries, adherence to evidence-based literature for treatment is key. Radiation therapy combined 
with chemotherapy are the mainstay of management for locally advanced cervical carcinoma. 
The treatment should ideally not exceed eight (8) weeks after the baseline work-up and dis-
ease evaluation to maximize disease control.
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